contemporarypediatrics.com Breaking News Headlines Today | Ground News

contemporarypediatrics.com image

News from contemporarypediatrics.com

See all of contemporarypediatrics.com news coverage in one place. Discover how contemporarypediatrics.com’s media bias informs their coverage and compare with thousands of other news outlets.

We’ve discovered 158 headlines written by contemporarypediatrics.com during the past 3 months.

contemporarypediatrics.com’s media bias is . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

contemporarypediatrics.com’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about contemporarypediatrics.com

Where is contemporarypediatrics.com located?contemporarypediatrics.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top contemporarypediatrics.com News

FDA Approves Zepbound as First Drug Treatment for Obstructive Sleep Apnea

FDA · United States

FDA Approves Zepbound as First Drug Treatment for Obstructive Sleep Apnea

61% Center coverage: 34 sources

The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in adults with obesity, the drugmaker Eli Lilly said Friday. The decision makes it the first drug treatment for the disorder, which affects about 39 million adults in the United States. See the Story

Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia

67% Center coverage: 3 sources

CRENESSITY, the first new treatment available in 70 years to the classic congenital adrenal hyperplasia (CAH) community, offers a paradigm-shifting treatment approachFDA approval supported by data from the largest-ever clinical trial program in pediatric and adult patients with classic CAHCRENESSITY…See the Story

What's Going On With Mesoblast Shares Thursday? - Mesoblast (NASDAQ:MESO)

History · United States

What's Going On With Mesoblast Shares Thursday? - Mesoblast (NASDAQ:MESO)

100% Center coverage: 2 sources

Mesoblast Limited (NASDAQ:MESO) stock is trading higher Thursday after the company announced the U.S. Food and Drug Administration (FDA) approved Ryoncil. The Details: Ryoncil is the first FDA approved therapy for children aged 2 months and older with steroid-refractory acute graft versus host disease (SR-aGvHD). Each year in the U.S., around 10,000 patients undergo an allogeneic bone marrow transplant, including 1,500 children. About 50% of the…See the Story

Latest News Stories

You've scrolled to the bottom of the feed, there are no more stories.

Donate Privacy Policy Manage Cookies Terms and Conditions

© 2024 Snapwise Inc